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homophilic DD interactions. In turn, FADD recruits the
zymogen form of the apoptosis-initiating protease cas-
pase-8, through homophilic interaction of ªdeath ef-
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1 DNA Way The mechanism of apoptosis signaling by TNFR1 is
similar to that of Fas, though not identical (AshkenaziSouth San Francisco, California 94080
and Dixit, 1998). Upon TNF binding, TNFR1 recruits the
adaptor TRADD, through homophilic DD interactions.
TRADD recruits FADD and caspase-8, initiating apo-Summary
ptosis. Alternatively, TRADD recruits the DD-containing
adaptor RIP to activate NF-kB and the adaptor TRAF-2Fas (APO-1/CD95) and tumor necrosis factor receptor
1 (TNFR1) trigger apoptosis by recruiting the apoptosis to activate the JNK/AP-1 pathway. Cells from trans-
genic mice expressing dominant-negative FADD mutantsinitiator caspase-8 through the adaptor FADD. Fas
binds FADD directly, whereas TNFR1 binds FADD indi- (FADD-DN) or from FADD gene knockout mice resist
apoptosis induction through Fas and TNFR1 (Newtonrectly, through TRADD. TRADD alternatively recruits
the NF-kB-inducing adaptor RIP. The TNF homolog et al., 1998; Yeh et al., 1998; Zhang et al., 1998; Zornig
et al., 1998), as do cells deficient in caspase-8 (Juo etApo2L/TRAIL triggers apoptosis through two distinct
death receptors, DR4 and DR5; however, receptor over- al., 1998; Varfolomeev et al., 1998). Thus, FADD and
caspase-8 are essential for apoptosis signaling throughexpression studies have yielded conflicting results on
the ligand's signaling mechanism. Apo2L/TRAIL in- Fas and TNFR1.
Apo2L/TRAIL (Apo2 ligand or TNF-related apoptosis-duced homomeric and heteromeric complexes of DR4
and DR5 and stimulated recruitment of FADD and cas- inducing ligand) was identified recently as an apoptosis-
inducing member of the TNF gene superfamily (Wiley etpase-8 and caspase-8 activation in nontransfected
cells. TRADD and RIP, which bound TNFR1, did not al., 1995; Pitti et al., 1996). The biological roles of Apo2L/
TRAIL are not fully understood, but there is evidencebind DR4 and DR5. Thus, Apo2L/TRAIL and FasL initiate
apoptosis through similar mechanisms, and FADD may for its involvement in apoptosis modulation within the
immune system, including T cell apoptosis (Ashkenazibe a universal adaptor for death receptors.
and Dixit, 1999), target killing by natural killer cells (John-
sen et al., 1999) and macrophages (Griffith et al., 1999),Introduction
and dendritic cell death (Wang et al., 1999). Apo2L/
TRAIL interacts with four cellular receptors that form aMembers of the TNF (tumor necrosis factor) gene super-
distinct subgroup within the TNFR superfamily. Deathfamily regulate development and function of the immune
receptor 4 (DR4) (Pan et al., 1997a) and DR5 (Pan etsystem (Gruss and Dower, 1995). TNF and most of its
al., 1997b; Sheridan et al., 1997) (also called TRAIL-R2,relatives are homotrimeric type II transmembrane pro-
TRICK2, or KILLER) (Screaton et al., 1997; Walczak etteins that interact with cognate members of the TNFR
al., 1997; Wu et al., 1997) have cytoplasmic DDs and(TNF receptor) superfamily. A subset of the TNFR super-
signal apoptosis. Decoy receptor 1 (DcR1) (Sheridan etfamily, known as ªdeath receptors,º share homology in
al., 1997) (also called TRID, TRAIL-R3, or LIT) (Degli-a cytoplasmic region dubbed the ªdeath domainº (DD)
Esposti et al., 1997a; Pan et al., 1997b; Mongkolsapaya(Ashkenazi and Dixit, 1998). Fas (also called APO-1 or
et al., 1998), is a phospholipid-anchored cell surfaceCD95) is critical for apoptosis during peripheral lympho-
protein that lacks a cytoplasmic tail. DcR2 (Marsterscyte deletion (Nagata, 1997), while TNFR1 plays a key
et al., 1997) (also called TRAIL-R4 or TRUNDD) (Degli-role in the inflammatory response, by modulating gene
Esposti et al., 1997b; Pan et al., 1998) has a truncatedexpression through NF-kB and AP-1 (Wallach et al.,
death domain that does not signal apoptosis induction.1999).
Apo2L/TRAIL binds also to a more distantly relatedThe mechanisms of apoptosis initiation by Fas and
TNFR homolog, osteoprotegerin, which is a secreted,TNFR1 have been well defined by biochemical and ge-
soluble receptor for the TNF homolog TRANCE/RANKL/netic methods (Nagata, 1997; Ashkenazi and Dixit, 1998;
OPGL (Emery et al., 1998).Thornberry and Lazebnik, 1998). FasL triggers a series
Despite several investigations, the mechanism of apo-of protein±protein interactions that leads to assembly
ptosis initiation by Apo2L/TRAIL remains unclear (Ash-of a death-inducing signaling complex (DISC) at the cy-
kenazi and Dixit, 1998). There are conflicting reportstoplasmic DD of Fas (Kischkel et al., 1995). Upon ligation,
on the effect of FADD-DN overexpression on apoptosisFas recruits the adaptor molecule FADD/Mort1, through
induction by overexpressed DR4 or DR5. Some studies
indicate inhibition (Chaudhary et al., 1997; Schneider et§ To whom correspondence should be addressed (e-mail: aa@
al., 1997; Walczak et al., 1997), while others do not (Pangene.com).
k These authors contributed equally to this work. et al., 1997a, 1997b; Sheridan et al., 1997). In addition,
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there is evidence that overexpressed FADD can associ-
ate with overexpressed DR4 or DR5 (Chaudhary et al.,
1997; Schneider et al., 1997), but this was not observed
in other studies (McFarlane et al., 1997; Pan et al., 1997a,
1997b). Thus, it is unknown whether FADD is a physio-
logical adaptor for DR4 and DR5. Besides FADD, overex-
pressed TRADD (Schneider et al., 1997) or TRADD and
RIP (Chaudhary et al., 1997) were reported to interact
with overexpressed DR4 or DR5, suggesting that these
receptors may assemble a signaling complex that re-
sembles that of TNFR1. FADD-deficient mouse embry-
onic fibroblasts (MEFs) undergo apoptosis upon overex-
pression of human DR4, suggesting the existence of a
FADD-independent pathway from DR4 to caspases (Yeh
et al., 1998). Evidence for caspase-8 involvement in apo-
ptosis induction by Apo2L/TRAIL is also conflicting.
Caspase-8 is processed in cells undergoing apoptosis
in response to Apo2L/TRAIL (Griffith et al., 1998; Muh-
lenbeck et al., 1998). In two independent studies, domi-
nant-negative caspase-10 mutants blocked apoptosis
induction by overexpressed DR4 or DR5, while blocking
by caspase-8-DN was inconsistent (McFarlane et al.,
1997; Pan et al., 1997b). Further, two different caspase-
10 mutations in patients with type II autoimmune lym-
phoproliferative syndrome have been implicated in lym-
phocyte resistance to Apo2L/TRAIL (Wang et al., 1999),
although subsequent study revealed that one of these
is in fact a common polymorphism in the Danish popula-
tion (Gronbaek et al., 2000). It is unknown whether en-
dogenous caspase-8 or -10 physically associates with Figure 1. The B Lymphoma Cell Line BJAB Expresses DR4 and DR5
endogenous DR4 and DR5. and Is Sensitive toward Apo2L/TRAIL-Induced Apoptosis
To investigate the molecular basis for apoptosis initia- (A) BJAB cells were stained with antireceptor mAbs and analyzed
tion by Apo2L/TRAIL, we analyzed the DISC that this by flow cytometry. Thin and thick lines show staining patterns of
background and indicated antibody, respectively. Data are repre-ligand assembles in nontransfected cells. We report the
sentative of three independent experiments.first direct evidence for Apo2L/TRAIL-induced recruit-
(B) Characterization of endogenous DR4 and DR5. Immunoprecipi-ment of endogenous FADD and caspase-8 to endoge-
tations (IP) with a control (Crtl IgG) and receptor-selective mAbsnous DR4 and DR5 in multiple cell lines. We show that
are shown. The IPs were resolved by SDS-PAGE and analyzed by
this ligand forms both homomeric and heteromeric com- Western blotting (WB) with the indicated antibody.
plexes with DR4 and DR5 and that each receptor can (C) Cells were incubated with 2 mg/ml anti-Flag (M2) mAb and various
concentrations of Flag-tagged ligand for 24 hr and analyzed forrecruit FADD and caspase-8 independently of the other
apoptosis. Data are means 6 SD of triplicates.receptor. These results indicate that Apo2L/TRAIL and
FasL engage similar pathways to apoptosis and support
the idea that FADD is a universal adaptor for death
the full-length 49 kDa form of DR5 is proteolytically de-receptors.
graded into the 43 kDa form (Walczak et al., 1997). Solu-
ble FasL does not induce apoptosis efficiently; however,Results
a Flag epitope±tagged version induces apoptosis upon
aggregation with anti-Flag mAb (Tanaka et al., 1998;BJAB Lymphoma Cells as a Model for
Huang et al., 1999). Although soluble homotrimericApo2L/TRAIL-Induced Apoptosis
Apo2L/TRAIL is biologically active (Ashkenazi et al.,To analyze the Apo2L/TRAIL DISC in comparison to the
1999; Walczak et al., 1999), to facilitate comparisonsFasL DISC, we characterized the B lymphoma cell line
with FasL, we generated a Flag-tagged version of eachBJAB, which is sensitive to both ligands (see below).
ligand. Apo2L/TRAIL-Flag and FasL-Flag induced dose-Flow cytometry with receptor-selective monoclonal an-
dependent apoptosis in BJAB cells in the presence oftibodies (mAbs) revealed cell surface expression of DR4
the anti-Flag M2 mAb (Figure 1C).and DR5, but not DcR1 or DcR2 (Figure 1A). Analysis
of BJAB cell supernatants by ELISA with anti-OPG mAbs
indicated less than detectable (1 ng/ml) levels of OPG Apo2L/TRAIL Stimulates Recruitment of FADD
and Caspase-8 in BJAB Cells(data not shown). Immunoprecipitation (IP) and Western
blot (WB) analysis of BJAB cell lysates with DR4 or DR5 To study DISC assembly, we stimulated BJAB cells with
Apo2L/TRAIL-Flag plus M2 mAb for 10 min to enablemAb revealed a single DR4 protein band of z45 kDa
and two DR5 bands of z49 kDa and z43 kDa (Figure 1B). ligand±receptor binding and recruitment of signaling
molecules. We then lysed the cells and captured ligand-The DR5 data is consistent with results from a previous
study, which also showed by peptide sequencing that associated complexes through IP of the M2 mAb with
FADD and Caspase-8 in the Apo2L/TRAIL DISC
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Figure 2. Apo2L/TRAIL Recruits DR4, DR5,
FADD, and Caspase-8 into the DISC in BJAB
Cells
Ligands (1 mg/ml) plus M2 mAb (2 mg/ml) were
added either after cell lysis (unstimulated) or
10 min before cell lysis (stimulated).
(A) IP of DR4 or DR5 through Apo2L/TRAIL.
Each receptor was visualized by WB.
(B) Characterization of DR4 and DR5 by direct
IP and 2D gel/WB analysis.
(C±F) 2D gel analysis of the Apo2L/TRAIL and
FasL DISC by metabolic labeling (C and D)
and subsequent WB (E and F). White arrow-
head pairs indicate 35S-labeled pro-caspase-8
isoforms (p55/53, upper doublet) and FADD
(lower doublet). Black arrows mark the corre-
sponding doublets of spots in the WB analy-
sis. Gray arrows indicate the processed forms
of caspase-8 (p43/41). White boxes surround
35S-labeled DR4 and DR5 spot areas.
protein A/G beads. Recruitment of cytoplasmic compo- Next, we labeled BJAB cells metabolically with
[35S]cysteine and [35S]methionine and analyzed Apo2L/nents to the DISC requires intact cells. Therefore, to
control for stimulation-independent components, we TRAIL-induced DISC formation by 2D gel analysis and
autoradiography. We detected both DR4 and DR5 byadded the ligand and M2 mAb after lysis of the cells for
IP (unstimulated control). Apo2L/TRAIL associated with this method (Figure 2C, white boxes, compare with Fig-
ure 2B). Two additional unique doublets of spots ap-DR4 and DR5 (Figure 2A); as expected, ligand±receptor
association was unaffected by cell lysis, because this peared in a stimulation-dependent manner (Figure 2C,
white arrowheads). This pattern was identical to theinteraction does not require cytoplasmic factors.
To examine DISC components closely, we analyzed pattern of spots in 2D gel analysis of FasL-stimulated
cells (Figure 2D), suggesting association of the sameIPs from unstimulated or stimulated cells by two-dimen-
sional (2D) gel electrophoresis. As a prelude for DISC DISC components. Fas was detectable only with pro-
longed exposures (data not shown), consistent withanalysis, we determined the positions of DR4 and DR5
on 2D gels by IP and WB with receptor-selective mAbs. published results (Kischkel et al., 1995). Previous 2D gel
studies on the Fas DISC identify the two doublets ofDR4 migrated as a series of spots of z45 kDa (Figure
2B), probably representing differentially glycosylated spots as FADD and caspase-8 (Kischkel et al., 1995;
Scaffidi et al., 1997). To confirm the identity of the spotsforms of the protein, which contains a potential N-linked
glycosylation site (Pan et al., 1997a; Sheridan et al., in the Apo2L/TRAIL DISC, we probed the membranes
that contained the electroblotted 35S-labeled proteins1997). DR5 migrated as two less diffuse spots of z49
kDa and z43 kDa (Figure 2B), consistent with the ab- with anti-FADD and anti-caspase-8 mAbs (Figures 2E
and 2F). The 2D gel positions of the immunodetectedsence of N-linked glycosylation sites in this receptor and
its previously observed degradation (Pan et al., 1997b; molecules matched the positions of the 35S-labeled pro-
teins, identifying the upper doublet of spots as the twoSheridan et al., 1997; Walczak et al., 1997).
Immunity
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we investigated a panel of cell lines (Figure 4). Flow
cytometry showed frequent coexpression of DR4 and
DR5, and low or undetectable expression DcR1 and
DcR2 (Figure 4A). Quantitative reverse transcriptase-
PCR analyses of receptor mRNA expression revealed
similar results, with two exceptions: (1) DR5 appeared
even more abundant then the other receptors at the
mRNA level, and (2) HCT116 and NCI-H460 cells showed
low yet detectable decoy receptor mRNA levels (data
Figure 3. Apo2L/TRAIL Does Not Recruit Endogenous TRADD or not shown). Apo2L/TRAIL induced marked levels of apo-
RIP in BJAB Cells ptosis in the tested cell lines (Figure 4B). Albeit with
RIP, TRADD, or FADD in BJAB cell lysates were detected either by some variation, Apo2L/TRAIL stimulated recruitment of
IP/WB (two left lanes) or by direct WB (last lane on right). Apo2L/
FADD and caspase-8 as well as caspase-8 processingTRAIL-Flag or FasL-Flag (1 mg/ml) plus M2 (2 mg/ml), or TNF (0.1
in all cases (Figure 4C). Some cell lines (e.g., MDA-MB-mg/ml) were added as indicated for 0, 10, or 60 min, and the cells
231) showed a much more prominent DISC at 10 minwere lysed and DISCs analyzed by IP with anti-TNFR1 for TNF or
through M2 for Apo2L/TRAIL or FasL. Signaling components in the than 60 min, suggesting that in these cells caspase-8
IPs were visualized by WB. processing is more rapid. These results indicate that
Apo2L/TRAIL recruits FADD and caspase-8 and induces
caspase-8 activation in multiple cell types.
isoforms of pro-caspase-8 (p55/p53) (Scaffidi et al.,
DR4 and DR5 Can Form Homomeric1997), and the lower doublet as phosphorylated (top)
and Heteromeric Complexesand unphosphorylated (bottom) FADD (Kischkel et al.,
Recent crystallographic studies demonstrate that solu-1995; Scaffidi et al., 2000). Immunodetection revealed
ble Apo2L/TRAIL is a homotrimeric molecule that is sta-also the existence of two proteolytically processed
bilized by a unique zinc binding site (Hymowitz et al.,forms of caspase-8 (p43/p41) (Figures 2E and 2F, gray
2000). The homomeric complex between soluble Apo2L/arrows), which are formed during caspase-8 activation
TRAIL and soluble DR5 extracellular domain contains(Medema et al., 1997; Scaffidi et al., 1997). These cas-
one ligand homotrimer and three DR5 molecules (Hy-pase-8 spots were weakly detectable in 35S-labeled gels
mowitz et al., 1999; Mongkolsapaya et al., 1999). It isfrom FasL-stimulated cells, but were not visible in
unknown, however, whether Apo2L/TRAIL can form het-Apo2L/TRAIL-stimulated cells, probably because of
eromeric complexes with both DR4 and DR5 at the cellmasking by the nearby DR4 and DR5 spots (Figure 2C).
surface. To investigate this possibility, we incubatedThus, Apo2L/TRAIL and FasL similarly induce recruit-
BJAB cells with buffer or Apo2L/TRAIL-Flag (without M2ment of endogenous FADD and caspase-8 to their death
mAb), lysed the cells, and subjected the lysates to IPreceptors in BJAB cells, leading to activation of cas-
with DR4 or DR5 mAbs. We used antibodies that dopase-8 by cleavage. We obtained similar results by stim-
not block ligand binding to capture both ligated andulation of BJAB cells with non-cross-linked trimeric
nonligated receptor, and mAbs that block ligand bindingApo2L/TRAIL and IP through the ligand or through DR4
to capture just the nonligated receptor. We detectedor DR5 (data not shown).
DR5 in a ligand-dependent manner in DR4 IPs generated
with nonblocking mAb (Figure 5A, bottom left panel).
We detected DR4 in a similar fashion in DR5 IPs (FigureAbsence of Endogenous TRADD or RIP
5A, top right panel). Neither DR4 nor DR5 was detectablein the Apo2L/TRAIL DISC in BJAB Cells
in blocking mAb IPs of the alternate, nonligated recep-Next, we examined whether Apo2L/TRAIL stimulates
tor, indicating that heterocomplex formation was ligand
recruitment of endogenous TRADD or RIP through en-
dependent. More uncleaved DR5 was coimmunoprecip-
dogenous DR4 and DR5 in BJAB cells (Figure 3). Both
itated with the nonblocking than the blocking DR4 mAb
TRADD and RIP were readily detectable in BJAB lysates (Figure 5A), suggesting that DR5 was less susceptible to
by direct WB or by IP/WB analysis, as was FADD. TNF degradation when complexed with ligand. The amount of
stimulated the recruitment of both TRADD and RIP to heteromeric complexes appeared to be smaller than the
TNFR1. In contrast, Apo2L/TRAIL and FasL each in- amount of homomeric complexes of ligated receptor
duced recruitment of FADD, consistent with the data in (compare right lane of top and bottom left panels, or
Figure 2, but not recruitment of TRADD or RIP. TNF did right lane of top and bottom right panels, of Figure 5A).
not stimulate recruitment of FADD to TNFR1, perhaps This raises the possibility that the ligand favors homo-
because of dominant activation of the NF-kB pathway. meric over heteromeric complexes; however, our experi-
Thus, in the absence of overexpression of receptors mental system might underestimate heteromeric com-
and adaptors and at least under the conditions used in plexes, because the nonblocking mAbs recognize both
these experiments, TNF induces receptor recruitment ligated and nonligated receptors. Regardless, Apo2L/
of TRADD and RIP, while Apo2L/TRAIL and FasL do not. TRAIL induces at least some formation of heteromeric
receptor complexes.
Apo2L/TRAIL Stimulates Recruitment of FADD DR4 and DR5 Can Recruit FADD and Caspase-8
and Caspase-8 in Various Cells Independently of Each Other
To assess whether recruitment of FADD and caspase-8 Given the ability of DR4 and DR5 to form heterocom-
plexes and their coexpression in many cell lines, weto the Apo2L/TRAIL DISC was unique to BJAB cells,
FADD and Caspase-8 in the Apo2L/TRAIL DISC
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Figure 4. Apo2L/TRAIL Recruits FADD and
Caspase-8 in Multiple Cell Lines
(A) Expression of DR4, DR5, DcR1, and DcR2
as analyzed by flow cytometry. Data are
means 6 SD of duplicates, and represent at
least two independent experiments. Specific
mean fluorescence was determined by sub-
traction of background fluorescence as mea-
sured with secondary antibody alone.
(B) Apoptosis induction. Cells were incubated
with 1 mg/ml Apo2L/TRAIL-Flag 1 2 mg/ml
M2 for 24 hr and then analyzed for apoptosis
in triplicates.
(C) One-dimensional Apo2L/TRAIL DISC anal-
ysis. Cells were incubated with Apo2L/TRAIL-
Flag (1 mg/ml) plus M2 (2 mg/ml) for 0, 10, or
60 min, lysed, and subjected to IP through
M2 and WB analysis.
investigated whether heterocomplex formation is re- implicated the adaptors FADD, TRADD, and RIP in
Apo2L/TRAIL signaling; however, the evidence for involve-quired for DISC assembly. In a survey of additional cell
lines, we identified some that expressed DR5 without ment of these molecules was based entirely on overex-
pression. Moreover, conflicting results were obtained byDR4, but none that expressed DR4 without DR5. Flow
cytometry showed that the glioma lines G55 and G142 different groups (Ashkenazi and Dixit, 1998). Compelling
evidence that FADD may not be required for apoptosisexpressed DR5, but not DR4, DcR1, or DcR2 (Figure 5B).
In both cell lines, Apo2L/TRAIL induced apoptosis (Fig- signaling by DR4 comes from experiments with FADD-
deficient MEFs (Yeh et al., 1998). In these cells, overex-ure 5C), as well as recruitment of FADD and caspase-8
and caspase-8 processing (Figure 5D). Hence, DR5 is pression of human DR4, but not of Fas, TNFR1, or DR3,
induced apoptosis.sufficient for recruiting these molecules into a functional
DISC. To study DR4 selectively, we stimulated BJAB To identify molecules that transmit the apoptosis sig-
nal emanating from Apo2L/TRAIL, we used a nonbiasedcells with a DR4 mAb that induces apoptosis upon
cross-linking with anti-Fc antibodies (Figure 5E). Cross- rather than a candidate-based approach. By metaboli-
cally labeling cells and co-IP of the DISC through ligand,linked DR5 mAb also induced apoptosis, and the combi-
nation of cross-linked DR4 and DR5 mAbs induced a we detected cellular components that associate with
the DISC in a stimulation-dependent manner. We foundroughly additive amount of cell death at the concentra-
tions used (Figure 5E). Cross-linked DR4 mAb induced that Apo2L/TRAIL induces recruitment of FADD and cas-
pase-8 to the DISC, and processing of caspase-8, whichrecruitment of FADD and caspase-8 (Figure 5F); DR5
was not detectable in DR4 IPs, confirming DR4-specific indicates its activation. Apo2L/TRAIL stimulated recruit-
ment of FADD and caspase-8 in all cell lines tested, andfunction. Thus, taken together, these findings indicate
that DR4 and DR5 can recruit FADD and caspase-8 and both DR4 and DR5 were independently able to recruit
these factors. Since the same DISC components wereinitiate apoptosis independently of each other.
recruited when either DR4 or DR5 or both receptors
were stimulated, it is likely that heterocomplexes of DR4Discussion
and DR5 are functionally equivalent to homomeric re-
ceptor complexes. Thus, we conclude that FADD andFADD May Be a Universal Adaptor for Death Receptors
Since the cloning of the two death receptors for Apo2L/ caspase-8 frequently constitute an apoptosis signaling
pathway for Apo2L/TRAIL. While we did not establishTRAIL, several studies have explored the mechanism of
apoptotic signaling through DR4 and DR5. This work that FADD or caspase-8 are necessary for Apo2L/TRAIL
Immunity
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Figure 5. DR4 and DR5 Can Form Heteromeric Complexes, but Each Can Recruit FADD and Caspase-8 Independently of the Other
(A) Ligand-dependent formation of receptor heterocomplexes in BJAB cells. Cells were stimulated with 1 mg/ml Apo2L/TRAIL-Flag for 10 min
(1) or left untreated (2). DR4 and DR5 were captured by IP with nonblocking (4G7 and 5C7, respectively) or blocking (1H5 and 3F11,
respectively) mAb and visualized by WB analysis.
(B) G55 and G142 cells express DR5 but not DR4, DcR1, or DcR2. Cells by flow cytometry as in Figure 1. The data is representative of three
independent experiments.
(C) Apo2L/TRAIL induces apoptosis in G55 and G142 cells. Cells were treated and analyzed as in Figure 4B.
(D) Apo2L/TRAIL stimulates recruitment of FADD and caspase-8 through DR5. Cells were treated and analyzed as in Figure 4C.
(E) Fc-cross-linked anti-DR4 or anti-DR5 mAbs induce apoptosis in BJAB cells. Cells were incubated with DR4 (4H6) or DR5 (3F11) mAb or
both mAbs (1 mg/ml) plus anti-Fc antibody (0.5 mg/ml), or Apo2L/TRAIL-Flag (1 mg/ml) plus M2 (2 mg/ml) for 24 hr and analyzed for apoptosis.
(F) DR4 cross-linking recruits FADD and caspase-8. BJAB cells were treated with cross-linked DR4 mAb (5 3 107 cells per lane) or Apo2L/
TRAIL-Flag plus M2 (1 3 107 cells per lane) as in (E) either after (2) or 10 min before (1) cell lysis. Lysates were subjected to IP with protein
A/G beads and WB analysis with the indicated antibodies.
function, the equal prominence of these factors in the Previous studies have yielded conflicting results with
respect to inhibition of apoptosis signaling by DR4 andApo2L/TRAIL and FasL DISC, together with their re-
quirement for apoptosis induction by FasL (Juo et al., DR5 by dominant-negative FADD and association of
FADD with these receptors (Chaudhary et al., 1997;1998; Varfolomeev et al., 1998; Yeh et al., 1998; Zhang
et al., 1998), suggests that these molecules are similarly McFarlane et al., 1997; Pan et al., 1997a, 1997b; Schnei-
der et al., 1997; Sheridan et al., 1997; Walczak et al.,important for signaling by both death ligands.
FADD and Caspase-8 in the Apo2L/TRAIL DISC
617
1997). Common to all these studies was the use of over- TRADD and RIP Are Not Prominent Components
of the Apo2L/TRAIL DISCexpression systems, in which the receptors and/or
FADD were present at nonphysiologically high levels. It The comparable prominence of FADD in the Apo2L/
TRAIL and FasL DISCs suggests that DR4 and DR5is possible that under such conditions the subcellular
localization and the stoichiometry of the overexpressed recruit FADD directly, similar to Fas. It has been pro-
posed on the basis of overexpression experiments thatcomponents were abnormal, hence skewing the ability
of receptor and adaptor molecules to interact. Notwith- DR4 and DR5 bind FADD indirectly, through TRADD
(Chaudhary et al., 1997; Schneider et al., 1997), and thatstanding, our data do not rule out the possibility that
other signaling molecules that may not be detected by TRADD also recruits RIP to these receptors (Chaudhary
et al., 1997). We examined these interactions in non-our methods also may link DR4 or DR5 to apoptosis. It
has been proposed that at least one mechanism that transfected BJAB cells. Whereas TNF stimulated the
recruitment of endogenous TRADD and RIP to its deathbypasses FADD can link Fas to apoptosis (Yang et
al., 1997); however, the complete resistance of FADD receptor, Apo2L/TRAIL and FasL did not. These results
support the possibility that DR4 and DR5 bind FADDknockout cells to Fas-mediated apoptosis suggests that
this pathway is not dominant (Yeh et al., 1998; Zhang directly, rather than through TRADD, and suggest that
the reported recruitment of TRADD and RIP to overex-et al., 1998). There is an apparent discrepancy between
the broad utilization of FADD by Apo2L/TRAIL and the pressed DR4 and DR5 may be artifactual. Thus, apo-
ptosis signaling by Apo2L/TRAIL resembles signalingobservation that DR4 kills FADD-deficient MEFs (Yeh
et al., 1998). Perhaps DR4 overexpression unmasks a by FasL rather than TNF.
FADD-independent death pathway in MEFs that DR4
can use more effectively than Fas. The physiological Mechanisms that May Control Sensitivity
significance of such a pathway is unclear, however, to Apo2L/TRAIL
since MEFs are naturally resistant to Apo2L/TRAIL (Var- DR4 and DR5 bind Apo2L/TRAIL with similar affinities
folomeev et al., 1998). (Degli-Esposti et al., 1997a). Our data suggest that DR4
Like TNFR1, the death receptor DR3 appears to bind and DR5 are also similar with respect to apoptosis sig-
FADD indirectly through TRADD, although the evidence naling. While these receptors are often coexpressed and
for this comes from overexpression experiments (Ash- are capable of forming heteromeric complexes with
kenazi and Dixit, 1998). Here we establish that FADD Apo2L/TRAIL, they each can signal apoptosis indepen-
interacts with DR4 and DR5 under physiologic condi- dently. The patterns of DR4 and DR5 mRNA expression
tions. Thus, FADD may be a universal adaptor for death in human tissues are different, though not without over-
receptors. It is notable in this context that mice deficient lap. One reason for the existence of two similar recep-
in FADD activity display not only defects in lymphocyte tors for Apo2L/TRAIL might be to enable tighter regula-
apoptosis, but also lethal defects in embryonic develop- tion of responsiveness in tissues. It is conceivable also
ment and in T cell proliferation in response to antigen that DR4 and DR5 have additional signaling functions
(Newton et al., 1998; Yeh et al., 1998; Zhang et al., 1998; that may be distinct.
Zornig et al., 1998). In contrast, mice deficient in FasL The biological roles of Apo2L/TRAIL are not fully de-
or Fas activity show defects in apoptosis, but not prolif- fined, although there is evidence implicating this ligand
eration (Nagata, 1997). Hence, death receptors other in several aspects of apoptosis in the immune system
than Fas may modulate nonapoptotic functions of (Ashkenazi and Dixit, 1999; Griffith et al., 1999; Johnsen
FADD. The interaction of DR4 and DR5 with FADD places et al., 1999; Wang et al., 1999). The Apo2L/TRAIL mRNA
them among the candidates for this latter function. is expressed in many human tissues, as are DR4 and
DR5 transcripts; yet most normal cells are resistant to
apoptosis induction by this ligand (Ashkenazi et al.,
Caspase-8 Is Involved in Apoptosis Signaling 1999; Walczak et al., 1999). Many tumor cell lines includ-
by Apo2L/TRAIL ing the ones studied here express DR4 and DR5, but
Previous work suggested that caspase-10, but not cas- little or no DcR1 and DcR2 protein, suggesting that in
pase-8, interacts with DR4 and DR5 (Pan et al., 1997b), cancer cells, the decoy receptors are generally not im-
while other studies implicated both caspases (McFar- portant regulators of sensitivity to Apo2L/TRAIL. In con-
lane et al., 1997; Wang et al., 1999). The similar pheno- trast, several normal tissues express DcR1 and/or DcR2,
type of mice deficient in FADD (Yeh et al., 1998; Zhang et which suggests that these receptors may contribute to
al., 1998) or caspse-8 (Varfolomeev et al., 1998) suggests the physiologic resistance of certain cells to Apo2L/
that both molecules act in a linear pathway and that TRAIL. An additional factor that may modulate sensitivity
caspase-10 cannot substitute for caspase-8. The pres- to Apo2L/TRAIL is the initiator-caspase inhibitor, c-FLIP
ence of caspase-8 in the Apo2L/TRAIL DISC indicates (Wallach, 1997). C-FLIP expression levels correlate with
that this caspase is involved in signaling by DR4 and sensitivity to Apo2L/TRAIL in certain melanoma cell lines
DR5; however, it does not rule out the possibility that (Griffith et al., 1998). There is no evidence, however, for
caspase-10 is involved as well. To date, physical associ- a causal connection between c-FLIP expression and
ation of endogenous caspase-10 and death receptors resistance to Apo2L/TRAIL. Further, c-FLIP expression
has not been shown. Caspase-10 has several isoforms, did not correlate with resistance to Apo2L/TRAIL in co-
the functions of which are unknown (Ng et al., 1999), lon, lung, or breast cancer cell lines (D. A. L. and A. A.,
and mAbs that distinguish these isoforms have not been unpublished data). In addition, resistance of T cells to
developed. Direct studies on the involvement of endoge- FasL during early phases of antigen±receptor stimula-
nous caspase-10 in Apo2L/TRAIL signaling await better tion appears to be independent of c-FLIP (Scaffidi et
al., 1999). Future studies should examine whether othercharacterization of this enzyme.
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CA, USA) 1 10% FBS 1 1000 U/ml Penicillin±Streptomycin (Lifeantiapoptotic molecules such as Bcl-2 or IAP family
Technologies). After 30±60 min of incubation at 378C, 0.5 mCi of amembers contribute to modulation of sensitivity to
35S-labeled mix of cysteine and methionine (Tran35S-Label, ICN) wasApo2L/TRAIL. Our identification of the endogenous sig-
added into the media. The cells were labeled for up to 24 hr at 378C,
naling factors that mediate apoptosis initiation by washed once with PBS, and lysed, and the lysates were subjected
Apo2L/TRAIL should facilitate the identification of po- to IP as described above. The first dimension isoelectrofocusing
(IEF) was performed with the precast Immobiline DryStrips in antential modulators that act at the level of the DISC.
IPGphor apparatus essentially following the manufacturer's instruc-
tions (Amersham Pharmacia Biotech, Inc.). Briefly, the IP was mixedExperimental Procedures
for 30 min at 308C with reducing sample buffer (9.8 M urea, 4%
nonidet P-40, 100 mM dithiothreitol [DTT], 2% IPG buffer and bromo-Cell Lines, Antibodies, and Reagents
phenol blue) and electrofocused in 7 cm ImmobilineR DryStrips (pHThe following human cell lines were used: B cell lymphoma BJAB
3±10 nonlinear) with the IPGphor. The following focusing protocol(gift from E. Humke, Genentech); colon carcinomas Colo 205, HCT
was used: 50 mA per strip at 208C; (1) 30 V for 16 hr (step and hold);116, HT-29; breast carcinoma MDA-MB-231; lung carcinomas NCI-
(2) 200 V for 3 hr (step and hold); (3) 3500 V for 1 hr 30 min (gradient);H460, SK-MES-1 (gift from E. Sauseville, NCI, Bethesda, MD); glio-
(4) 3500 V for 1 hr 30 min (step and hold). The settings resulted inmas G55, G142 (gift from M. Westphal, Universitaetskrankenhaus
a total of 9105 Vh. After electrofocusing, the strips were either storedEppendorf, Hamburg, Germany); rhabdomypsarcoma KYM-1D4 (gift
at 2708C or shaken for 10 min at ambient temperature with equilibra-from A. Meager, NIBSC, WHO, Hertfordshire, UK). BJAB cells were
tion buffer (50 mM Tris-HCl [pH 7.5], 6 M urea, 30% glycerol, 2%cultured in RPMI 1640 1 10% heat-inactivated fetal bovine serum
SDS, 10 mg/ml DTT) and subjected to SDS-PAGE. The second di-(FBS) 1 1000 U/ml Penicillin±Streptomycin (Life Technologies,
mension was performed with a precast 10% Bis Tris NuPAGE gelRockville, MD), whereas the other cell lines were grown in 50:50
system, and the gels were then electrotransfered on nitrocellulosemedia (50% HAM's F-12; 50% DMEM) 1 10% FBS 1 1000 U/ml
membranes following the manufacturer's instructions (Novex, SanPenicillin±Streptomycin (Life Technologies). The primary antibodies
Diego, CA). The blots were air dried for 2 hr at 378C and exposedanti-FADD, anti-RIP, and anti-TRADD were purchased from Trans-
to BAS-III imaging plates (Fuji Photo Film, Inc., Greenwood, SC).duction Laboratories (Lexington, KY), anti-Caspase-8 from Upstate
The plates were read using the BAS-2000 IP Scanner with the ImageBiotechnology (Lake Placid, NY), and anti-FLAG (M2) from Sigma
Reader V1.2 software and then analyzed with the MacBAS V.2.4(St. Louis, MO). Anti-DR4 (1H5, 4H6, 4G7, 3G1, 4E7), anti-DR5 (3F11,
software (Fuji Photo Film, Inc., Greenwood, SC).5C7, 3H1), anti-DcR1 (6D10), anti-DcR2 (1G9) mAbs were generated
by using receptor±Fc fusion proteins as antigens. As secondary
Immunodetectionreagents, we used: horseradish peroxidase (HRP) ±conjugated goat
One-dimensional analysis of IPs was identical to the second dimen-a-mouse IgG2a and IgG2b from Southern Biotechnology Associ-
sion of the 2D gel analysis, omitting the IEF. The membranes wereates, Inc. (Birmingham, AL), HRP-conjugated goat anti-mouse IgG1
rehydrated in PBS containing 0.1% Tween-20 and blocked with 5%from PharMingen (San Diego, CA), HRP-conjugated streptavidin
milk in PBS. The concentration of all primary antibodies was 1 mg/(Amersham Pharmacia Biotech, Inc., Piscataway, NJ), fluorescein
ml. The dilution for the secondary antibodies and the developingisothiocyanate (FITC) ±conjugated F(ab9)2 goat anti-mouse IgG 1
reagent are indicated in brackets. For caspase-8 and FADD analysis,IgM from Jackson ImmunoResearch Labs, Inc. (West Grove, PA),
the membrane were cut at about 32 kDa and the upper part wasand goat anti-mouse IgG g-specific (anti-Fc) from Roche Molecular
probed with anti-caspase-8 (1:20000 anti-IgG2b-HRP, ECL),Biochemicals (Mannheim, Germany). The ligands were purified over
whereas for the lower part anti-FADD (1:10000 anti-IgG1-HRP, Su-an M2-Agarose column (Apo2L/TRAIL-Flag [amino acids 114±281]
perSignal) was used. Other blots were treated with a-TRADDin pFLAG-MAC [Sigma] expressed in E. coli and FasL-Flag [amino
acids 131±281] in pCMV-1 [Sigma] expressed in CHO cells). Recom- (1:10000 anti-IgG1-HRP, SuperSignal), anti-RIP (1:10000 anti-IgG2a-
binant human TNF was produced by Genentech. As substrates for HRP, SuperSignal), biotinylated anti-DR4 (3G1) and anti-DR5 (3H1)
immunodetection, either ECL (Amersham) or SuperSignal West Dura (1:5000, ECL and SuperSignal).
Extended Duration Substrate (Pierce, Rockford, IL) were used.
Apoptosis Assay
Flow Cytometry Cells were treated with indicated reagents for 24 hr. Percentage of
Cells (106) were washed once with PBS and resuspended in 1 ml apoptotic cells was determined by quantitation of DNA fragmenta-
cold FACS buffer (13 PBS, 3% FBS) containing the primary antibody tion, through analysis of propidium iodide stained nuclei by FACS-
(2 mg/ml of anti-DR4 [4E7], 10 mg/ml of anti-DR5 [3F11], and 2 mg/ can using the CELLQuest software (Becton Dickinson, Franklin
ml of anti-DcR1 or anti-DcR2). Cells were stained on ice for 60 min, Lakes, NJ), as described (Nicoletti et al., 1991).
then washed with 3 ml cold FACS buffer, and incubated with the
secondary antibody (1:100 dilution of FITC-conjugated goat anti- Acknowledgments
mouse IgG 1 IgM) at 48C for 60 min in the dark. After an additional
3 ml wash with FACS buffer, 10,000 cells per sample were analyzed We thank E. Sauseville, M. Westphal, and A. Meager for cell lines,
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with ligand (1 mg/ml Apo2L/TRAIL-Flag or FasL-Flag 1 2 mg/ml M2 synthesis.
or 100 ng/ml TNF) or left untreated (unstimulated). After one wash
with PBS, the cells were lysed for 30 min on ice with lysis buffer Received February 29, 2000; revised April 27, 2000.
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